Valuation: Vivoryon Therapeutics N.V.

Market Cap 34.06M 38.76M 31.79M 29.17M 54.61M 3.71B 55.96M 377M 147M 1.84B 146M 142M 6.35B P/E 2026 *
-3.59x
P/E 2027 * -3.71x
Enterprise Value 37.15M 42.27M 34.67M 31.82M 59.57M 4.05B 61.04M 411M 161M 2B 159M 155M 6.93B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
82.01%
Yield 2026 *
-
Yield 2027 * -
1 day+0.87%
1 week-5.69%
Current month+7.41%
1 month+8.92%
3 months-10.77%
6 months-22.87%
Current year-18.31%
1 week 1.15
Extreme 1.15
1.22
1 month 1.06
Extreme 1.06
1.5
Current year 1
Extreme 1
1.65
1 year 1
Extreme 1
1.84
3 years 0.41
Extreme 0.41
14.1
5 years 0.41
Extreme 0.41
22.58
10 years 0.41
Extreme 0.41
24.4
Manager TitleAgeSince
Chief Executive Officer 66 2023-08-13
Director of Finance/CFO - 2024-02-29
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 56 2006-12-31
Director/Board Member 66 2023-09-14
Director/Board Member 58 -
Date Insider Type Main position Quantity % Market Cap.
10/23/25 Free

Chief Operating Officer

20,000 0.0767%
10/23/25 Buy

Chief Executive Officer

135,000 0.5179%
10/23/25 Free 20,000 0.0767%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-5.69%-19.56%-91.62% 38.81M
+2.61%+7.16%-0.93%+13.78% 47.88B
-1.13%+0.31%+396.06%+599.39% 39.09B
-0.88%+2.86%+7.63%+53.61% 36.75B
+1.62%+24.06%+26.59%+10.07% 40.55B
+1.47%+4.90%+6.48%+43.52% 27.96B
-0.40%+1.28% - - 16.77B
+3.38%+11.91%+31.95%+133.45% 15.94B
+0.18%-2.75%+3.22%+9.68% 13.55B
+0.05%+7.84%-2.60%-28.24% 13.81B
Average +0.84%+3.62%+49.87%+82.63% 25.23B
Weighted average by Cap. +0.85%+5.06%+74.26%+125.44%

Financials

2026 *2027 *
Net sales - -
Net income -8.71M -9.91M -8.13M -7.46M -13.97M -949M -14.31M -96.41M -37.7M -470M -37.22M -36.41M -1.62B -8.71M -9.91M -8.13M -7.46M -13.97M -949M -14.31M -96.41M -37.7M -470M -37.22M -36.41M -1.62B
Net Debt 3.09M 3.52M 2.88M 2.65M 4.96M 337M 5.08M 34.2M 13.38M 167M 13.2M 12.92M 576M 11.8M 13.43M 11.01M 10.11M 18.92M 1.29B 19.39M 131M 51.08M 637M 50.42M 49.32M 2.2B
Logo Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Vivoryon Therapeutics N.V. has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer.
Employees
13
Date Price Change Volume
26-07-29 1.160 +0.87% 13,468
26-07-28 €1.150 -1.71% 9,381
26-07-27 €1.170 -0.85% 20,778
26-07-24 €1.180 +1.29% 6,318
26-07-23 €1.165 -5.28% 70,550
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.150EUR
Average target price
6.850EUR
Spread / Average Target
+495.65%

Annual profits - Rate of surprise